You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
IDBS provides enterprise solutions for scientific data management, analytics, and modeling including the E-WorkBook Suite.
The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year.
The company has shut down the Veris molecular diagnostics product line, which Beckman Coulter spent years developing, as a result of its acquisition of Cepheid.
The firm's European subsidiary is offering the new senior notes to repay, in part, all outstanding aggregate principal amounts on senior notes due later this month.
The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio.
Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.
This week's news includes Alere, Fulget Diagnostics, Trovagene, Great Basic Scientific, Interleukin, and Danaher.
The company beat Wall Street analysts' expectations for sales and earnings per share during the quarter.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.